GLA and Fabry disease: Agalsidase alfa treatment has previously been reported to be associated with slowing progression of renal and cardiac manifestations, with reduction of neuropathic pain and gastrointestinal symptoms, and with reduced mortality, in FD [[19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31]].